Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Array Biopharma Inc (ARRY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,170,379
  • Shares Outstanding, K 212,920
  • Annual Sales, $ 173,770 K
  • Annual Income, $ -147,350 K
  • 36-Month Beta 1.13
  • Price/Sales 18.25
  • Price/Cash Flow N/A
  • Price/Book 14.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.20
  • Number of Estimates 5
  • High Estimate -0.12
  • Low Estimate -0.24
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.56 +12.82%
on 09/14/18
15.71 -2.61%
on 08/30/18
+1.44 (+10.39%)
since 08/21/18
3-Month
13.31 +14.95%
on 08/20/18
19.88 -23.04%
on 06/22/18
-4.25 (-21.74%)
since 06/21/18
52-Week
9.98 +53.31%
on 10/27/17
20.21 -24.29%
on 06/21/18
+3.83 (+33.39%)
since 09/21/17

Most Recent Stories

More News
European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma

Array BioPharma Inc. (NASDAQ: ARRY) today announced that the European Commission (EC) has approved BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with unresectable or metastatic...

ARRY : 15.30 (+2.75%)
Watch for Array Biopharma to Potentially Pullback After Gaining 7.65% Yesterday

Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $13.98 to a high of $14.89. Yesterday, the shares gained 7.6%, which took the trading range above the 3-day high of...

ARRY : 15.30 (+2.75%)
Today's Research Reports on Trending Tickers: Array BioPharma and Intercept Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / August 22, 2018 / U.S. markets continue to edge higher on Tuesday as optimism over trade talks and upbeat earnings pushed equities into the green. Additionally, the Federal...

ARRY : 15.30 (+2.75%)
ICPT : 114.17 (-3.94%)
Array Biopharma Set to Possibly Rebound After Yesterday's Selloff of 2.34%

Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $13.53 to a high of $14.07. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $13.64...

ARRY : 15.30 (+2.75%)
Interesting ARRY Put And Call Options For June 2019

Investors in Array BioPharma Inc. saw new options become available today, for the June 2019 expiration.

ARRY : 15.30 (+2.75%)
After Yesterday's Decline of 3.21%, Array Biopharma Offers Investors Better Value

Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $13.58 to a high of $15.30. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $14.51...

ARRY : 15.30 (+2.75%)
Array BioPharma (ARRY) Reports Q4 Loss, Misses Revenue Estimates

Array BioPharma (ARRY) delivered earnings and revenue surprises of 0.00% and -3.11%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

ARRY : 15.30 (+2.75%)
Array BioPharma Names Carrie S. Cox Chairman of its Board of Directors

Array BioPharma Inc. (Nasdaq: ARRY) today announced that Carrie S. Cox has been named Chairman of its Board of Directors, effective immediately. Ms. Cox has been appointed to the Audit and Corporate Governance...

ARRY : 15.30 (+2.75%)
Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 on August 14, 2018

Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2018 and hold a conference call to discuss those results on Tuesday, August 14, 2018. Ron...

ARRY : 15.30 (+2.75%)
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer

Array BioPharma Inc. (NASDAQ: ARRY) today announced it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for encorafenib (BRAFTOVI(TM)), in combination with...

ARRY : 15.30 (+2.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade ARRY with:

Business Summary

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory...

See More

Key Turning Points

2nd Resistance Point 15.71
1st Resistance Point 15.51
Last Price 15.30
1st Support Level 14.90
2nd Support Level 14.49

See More

52-Week High 20.21
Fibonacci 61.8% 16.30
Last Price 15.30
Fibonacci 50% 15.09
Fibonacci 38.2% 13.89
52-Week Low 9.98

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar